Clomiphene Citrate (CC) Co-treatment With HP Urinary FSH vs HP Urinary FSH in CC-resistant PCOS
2013年5月29日 更新者:Mohamad Elsaid Ghanem、Mansoura Integrated Fertility Center
Clomiphene Citrate Co-treatment With Low Dose HP Urinary FSH vs. HP Urinary FSH Step-up Protocol for Clomiphene-citrate Resistant PCOS Anovulatory Infertility: Randomized Controlled Trial
To test whether adding small doses of HP urinary FSH to standard regimen of clomiphene citrate in clomiphene resistant PCOS well yield better results in terms of better ovulation rate,lower follicle number, less consumption of HP urinary FSH,lower treatment cost , better pregnancy rate, lower multiple pregnancy rates compared with the exclusive use of HP urinary FSH in these cases.
研究概览
详细说明
To test whether CC co- treatment with chronic low dose HP uFSH vs chronic low dose HP uFSH in CC resistant PCOS will yield better results in terms of ,ovulation rate, lower follicle number,lower HP uFSH dose ,better outcome in terms of pregnancy rates, better cost-effectiveness ratio, lower multiple pregnancy rates,lower cycle cancellation.
研究类型
介入性
注册 (实际的)
174
阶段
- 不适用
联系人和位置
本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。
学习地点
-
-
Dekahlia
-
Mansoura、Dekahlia、埃及
- Mansoura Integrated Fertility Center
-
-
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
18年 至 38年 (成人)
接受健康志愿者
不
有资格学习的性别
女性
描述
Inclusion Criteria:
- CC resistant PCOS
- Infertile
- Females
- Age 18-38
Exclusion Criteria:
- Hyperprolactinaemia
- Cushing syndrome
- Adult onset adrenal hyperplasia
- Age >38
- Other infertility factors in the couple than PCOS: male factor,tubal factor,edometriosis
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Clomiphene Citrate plus HP uFSH
Starting from the 2nd day of the cycle Clomiphene Citrate( CC)50 mg tablets are given in 100 mg daily dose for 5 days together with an low dose HP uFSH (half ampoule: 37.5 IU) given im daily for 8-10 days.
|
Clomiphene citrate 50 mg tab oral tablets(Clomid 50 mg tablets Global Napi , Egypt) two tablets(100 mg) /day are started from the 2nd day of cycle for 5 days togeteher with 37.5 IU HP uFSH (Fostimone 75 IU IBSA)/day for 8 days and may be extended to 10-12 days until leading follicle diameter reaches 18 mm
|
|
有源比较器:Step-up HP uFSH
HP uFSH started in doses of half ampole (37.5 )IU daily from the 2nd day of cycle for 7 days ,then dose is stepped-up to one ampoule ( 75 IU) for 7 days then the one and a half amps (112.5)
IU /day until follicular diameter reaches 18 mm mean diameter
|
HP u FSH (Fostimone 75 IU ,IBSA Institut Biochimique SA-CH 6903 Lugano) in doses of 37.5 IU (half ampole) im /day statrted from second day of the cycle for 7 days ,then increased to 75 IU for another 7 days ,then to 112.5 IU (one and half ampoule) untilleading follicle mean diameter reaches 18 mm
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
ovulation rate
大体时间:6 months
|
IF CC Co-treatment with low dose step-up HP urinary(u)FSH results in similar or higher ovulation rate compared with step-up low dose HP uFSH
|
6 months
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Live birth rate
大体时间:6 months
|
% of of cases that result in live birth > 20 weeks pregnancy
|
6 months
|
|
number of follicles sized 16 mm or more mean diameter in both ovaries at the time of hCG
大体时间:3 months
|
To test if CC-co treatment with low dose HP uFSH results in lower number of follicles 16 mm mean diameter or more at time of triggerring ovulation compared with low dose HP uFSH
|
3 months
|
|
Endometrial thickness
大体时间:3 months
|
Measuring endometrial thickness in mm in both study arms at the time of ovulation trigerring to see if there is difference
|
3 months
|
|
serum Estradiol(E2)
大体时间:3 months
|
serum level of E2 is measured in both groups at the time of ovulation triggerring to test for differences
|
3 months
|
|
incidence of multiple pregnancy
大体时间:3 months
|
To test if CC-co treatment with low dose HP uFSH results in lower or higher incidence of multiple pregnancies compared with low dose HP uFSH
|
3 months
|
|
costs per cycle
大体时间:3 months
|
costs of drugs used to induce ovulation in each arm of the study in Egyptian pounds The cost of HP uFSH per cycle was calculated by multiplying the cost of a single IU with the mean number of FSH IU used per cycle.
Add to this the cost of clomiphene citrate in the relevant arm
|
3 months
|
|
cost effectiveness ratio
大体时间:6 months
|
The cost-effectiveness ratio is calculated multiplying the cost per cycle by the total number of cycles performed in each arm then dividing the result for the number of clinical pregnancies obtained in the arm during the trial.
|
6 months
|
|
clinical and biochemical predictors of response to treatment
大体时间:6 weeks
|
6 weeks
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
调查人员
- 学习椅:Mohamad E Ghanem, MD、Mansoura Integrated Fertility Center
- 研究主任:Mohammad A Emam, MD、Mansoura Integrated Fertility Center
- 首席研究员:Mohamad E Ghanem, MD、Mansoura Integrated Fertility Center
出版物和有用的链接
负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。
一般刊物
- Palomba S, Falbo A, Zullo F. Management strategies for ovulation induction in women with polycystic ovary syndrome and known clomifene citrate resistance. Curr Opin Obstet Gynecol. 2009 Dec;21(6):465-73. doi: 10.1097/GCO.0b013e328332d188.
- Gorry A, White DM, Franks S. Infertility in polycystic ovary syndrome: focus on low-dose gonadotropin treatment. Endocrine. 2006 Aug;30(1):27-33. doi: 10.1385/ENDO:30:1:27.
- Ghanem ME, Elboghdady LA, Hassan M, Helal AS, Gibreel A, Houssen M, Shaker ME, Bahlol I, Mesbah Y. Clomiphene citrate co-treatment with low dose urinary FSH versus urinary FSH for clomiphene resistant PCOS: randomized controlled trial. J Assist Reprod Genet. 2013 Nov;30(11):1477-85. doi: 10.1007/s10815-013-0090-2. Epub 2013 Sep 7. Erratum In: J Assist Reprod Genet. 2014 Apr;31(4):505-6.
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始
2010年1月1日
初级完成 (实际的)
2012年9月1日
研究完成 (实际的)
2012年9月1日
研究注册日期
首次提交
2010年9月29日
首先提交符合 QC 标准的
2010年9月29日
首次发布 (估计)
2010年9月30日
研究记录更新
最后更新发布 (估计)
2013年5月30日
上次提交的符合 QC 标准的更新
2013年5月29日
最后验证
2013年5月1日
更多信息
与本研究相关的术语
其他研究编号
- MansouraIFC1
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.